Adaptive Biotechnologies (MUN:1HM) - Aandelenkoers, Nieuws & Analyse

1HM Overzicht aandelen

Adaptive Biotechnologies Corporation, een bedrijf in een commerciële fase, ontwikkelt een immuungeneesmiddelenplatform voor de diagnose en behandeling van verschillende ziekten. Meer informatie

1HM fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 18.47% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Adaptive Biotechnologies Corporation Concurrenten

Evotec

XTRA:EVT

€1.5b

Gerresheimer

XTRA:GXI

€2.6b

SCHOTT Pharma KGaA

XTRA:1SXP

€4.0b

Sartorius

XTRA:SRT3

€13.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Adaptive Biotechnologies
Historische aandelenkoersen
Huidige aandelenkoers	US$5.65
52 Week Hoogtepunt	US$5.65
52 Week Laag	US$3.44
Bèta	1.45
11 maand verandering	n/a
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	-77.32%
Verandering sinds IPO	-82.87%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	1HM	DE Life Sciences	DE Markt
7D	0%	2.2%	0.2%
1Y	n/a	3.6%	8.5%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 1HM presteerde ten opzichte van de German Life Sciences.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 1HM presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is 1HM's price volatile compared to industry and market?
1HM volatility
1HM Average Weekly Movement	n/a
Life Sciences Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stabiele aandelenkoers: De aandelenkoers van 1HM is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 1HM in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	709	Chad Robins	www.adaptivebiotech.com

Adaptive Biotechnologies Corporation, een bedrijf in een commerciële fase, ontwikkelt een immuunmedicijnplatform voor de diagnose en behandeling van verschillende ziekten. Het bedrijf biedt een immunosequencing-platform dat een combinatie is van eigen chemie, computationele biologie en machinaal leren om klinische immunomics-gegevens te genereren om het adaptieve immuunsysteem te decoderen. Het bedrijf levert ook de clonoSEQ diagnostische test die het resterende aantal kankercellen detecteert en controleert dat aanwezig is in het lichaam van een patiënt tijdens en na de behandeling, bekend als Minimal Residual Disease (MRD).

Adaptive Biotechnologies Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Adaptive Biotechnologies zich tot de beurswaarde?
1HM fundamentele statistieken
Marktkapitalisatie	€664.67m
Inkomsten(TTM)	-€187.49m
Inkomsten(TTM)	€170.24m

3.9x

P/S-verhouding

-3.5x

Koers/Winstverhouding

Is 1HM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
1HM resultatenrekening (TTM)
Inkomsten	US$177.28m
Kosten van inkomsten	US$182.16m
Brutowinst	-US$4.88m
Overige uitgaven	US$190.37m
Inkomsten	-US$195.24m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.32
Brutomarge	-2.75%
Nettowinstmarge	-110.13%
Schuld/Eigen Vermogen Verhouding	59.4%

Hoe presteerde 1HM op de lange termijn?

Bekijk historische prestaties en vergelijking

1HM Overzicht aandelen

Beloningen

Risicoanalyse

Adaptive Biotechnologies Corporation Concurrenten

XTRA:EVT

€1.5b

XTRA:GXI

€2.6b

XTRA:1SXP

€4.0b

XTRA:SRT3

€13.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Adaptive Biotechnologies Corporation to Report Q3, 2024 Results on Nov 07, 2024

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Insufficient new directors

Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024

Recent updates

Adaptive Biotechnologies Corporation to Report Q3, 2024 Results on Nov 07, 2024

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Insufficient new directors

Adaptive Biotechnologies Corporation to Report Q2, 2024 Results on Aug 01, 2024

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024

Adaptive Biotechnologies Corporation Announces CFO Changes

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024

Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024

Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting

Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023

Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023

Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ

Insufficient new directors

Adaptive Biotechnologies Corporation Announces Executive Changes

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Insufficient new directors

Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the Board

Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2023

Adaptive Biotechnologies Corporation Provides Revenue Guidance for Full Year 2023

Adaptive Biotechnologies Corporation to Report Q4, 2022 Results on Feb 14, 2023

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease in Patients with Diffuse Large B-Cell Lymphoma Using Circulating Tumor DNA

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Chief Commercial Officer of MRD recently sold €190k worth of stock

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.35 loss in 2Q 2021)

Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation to Report Q2, 2022 Results on Aug 03, 2022

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

Adaptive Biotechnologies Corporation Includes in Several Abstracts Investigating the Impact of Mrd in Blood Cancers At the American Society of Clinical Oncology

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.29 loss in 1Q 2021)

Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2022

Adaptive Biotechnologies Corporation to Report Q1, 2022 Results on May 04, 2022

President recently sold €51k worth of stock

Adaptive Biotechnologies Corporation Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease

Adaptive Biotechnologies Corporation Announces CFO Changes

Adaptive Biotechnologies Corporation Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

Adaptive Biotechnologies Corporation Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

Adaptive Biotechnologies Corporation Provides Earnings Guidance for Full Year 2021

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.26 loss in 2Q 2020)

Adaptive Biotechnologies Corporation Announces New Study Published in Nature Provides Further Evidence COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.25 loss in 1Q 2020)

Adaptive Biotechnologies Corporation Provides Financial Guidance for 2021

Insider recently sold €128k worth of stock

Adaptive Biotechnologies Corporation Announces Board Changes

Independent Director has left the company

Independent Director has left the company

Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

New 90-day low: €36.40

Adaptive Biotechnologies Corporation and Genentech, Inc. Collaborate the Development of Cellular Therapy Drugs for Treating Cancer by Targeting Immune Cells to Specific Shared and Personalized Cancer-Related Antigen Targets

Full year 2020 earnings released: US$1.11 loss per share (vs US$1.01 loss in FY 2019)

Revenue beats expectations

Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio

Adaptive Biotechnologies Corporation to Report Q4, 2020 Results on Feb 24, 2021

Adaptive Biotechnologies Corporation Announces Executive Changes